Description
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide composed of fifteen amino acids, derived from a protein sequence originally identified in human gastric juice [5]. Its sequence is entirely stable under physiological conditions, distinguishing it from many endogenous peptides that degrade rapidly in biological environments [1]. The compound carries the molecular designation PL-10 in some literature and is sometimes referred to as a stable gastric pentadecapeptide to reflect both its origin and its resistance to breakdown [4].
Structurally, BPC-157 is a linear oligopeptide without disulfide bridges, a characteristic that contributes to its chemical tractability in laboratory settings [5]. Preclinical investigations have examined its interactions with several signaling pathways, including those governing growth hormone receptor expression, angiogenesis, and pro-inflammatory cytokine modulation [3]. These pathway-level properties make it a subject of interest for researchers studying tissue homeostasis and cellular repair mechanisms in controlled experimental models.
Research groups have applied BPC-157 across a range of preclinical study contexts. Musculoskeletal models have been a primary focus, with investigators examining its effects on tendon, ligament, skeletal muscle, and bone in rodent injury paradigms [2][3]. Additional areas of preclinical inquiry include gastrointestinal mucosal integrity, wound-healing dynamics, and vascular responses such as those observed in ischemia-reperfusion models [4]. A 2025 literature and patent review noted its pleiotropic activity profile and growing presence in published research and intellectual property filings [1].
The majority of studies to date have been conducted in small-animal models, and BPC-157 has not received approval from the FDA or other major regulatory bodies for any clinical application [1][5]. Its continued use as a laboratory research tool reflects ongoing scientific interest in understanding the molecular mechanisms underlying its observed preclinical activity [3].
---
References
[1] Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel, Switzerland), 2025. https://pubmed.ncbi.nlm.nih.gov/40005999/
[2] Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and tissue research, 2019. https://pubmed.ncbi.nlm.nih.gov/30915550/
[3] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/
[4] Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in pharmacology, 2021. https://pubmed.ncbi.nlm.nih.gov/34267654/
[5] BPC-157. Wikipedia. https://en.wikipedia.org/wiki/BPC-157
